SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-20-224087
Filing Date
2020-08-19
Accepted
2020-08-19 06:08:59
Documents
12
Period of Report
2020-09-29
Effectiveness Date
2020-08-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A d34917ddef14a.htm DEF 14A 346657
2 GRAPHIC g34917g15g55.jpg GRAPHIC 26545
3 GRAPHIC g34917g45u30.jpg GRAPHIC 33208
4 GRAPHIC g34917g48b23.jpg GRAPHIC 8396
5 GRAPHIC g34917logo1.jpg GRAPHIC 16150
6 GRAPHIC g34917logo2.jpg GRAPHIC 8430
7 GRAPHIC g34917logo3.jpg GRAPHIC 9030
8 GRAPHIC g34917logo4.jpg GRAPHIC 8463
9 GRAPHIC g34917logo5.jpg GRAPHIC 8203
10 GRAPHIC g34917logo6.jpg GRAPHIC 8108
11 GRAPHIC g34917logo7.jpg GRAPHIC 9006
12 GRAPHIC g34917logo8.jpg GRAPHIC 9042
  Complete submission text file 0001193125-20-224087.txt   489967
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36510 | Film No.: 201115280
SIC: 2834 Pharmaceutical Preparations